Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTRANS vs MEMBRANEBLUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Treatment of opioid dependence (as part of medication-assisted treatment)
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Primarily metabolized by CYP3A4 to norbuprenorphine; also undergoes conjugation with glucuronic acid. Norbuprenorphine is active and further glucuronidated.
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
96% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
Vd: 2-5 L/kg, indicating extensive tissue distribution
0.35-0.45 L/kg, indicating primarily extracellular distribution.
Transdermal: 15-25%; buccal: 60-70%
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider starting at the lowest dose (5 mcg/h) with close monitoring for adverse effects.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Start at the lowest dose (5 mcg/h) and titrate cautiously; consider reducing dose by 50%. Child-Pugh Class C: Avoid use due to increased risk of toxicity.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
Not recommended for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Initiate at the lowest dose (5 mcg/h) and titrate slowly with careful monitoring for respiratory depression, sedation, and falls. Consider age-related reductions in renal and hepatic function.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
Risk of respiratory depression, addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome; risk of potentially fatal respiratory depression when used with benzodiazepines or other CNS depressants; and risk of life-threatening respiratory depression in children with accidental ingestion.
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; risk with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; biliary tract disease; use in elderly and debilitated patients; hepatic impairment; renal impairment; pregnancy; lactation.
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially increasing buprenorphine levels. No other significant food interactions documented.
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use near term due to risk of respiratory depression. Generally, buprenorphine is considered lower risk than full agonists but still requires careful risk-benefit assessment.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
Buprenorphine is excreted into breast milk. M/P ratio approximately 0.3 (range 0.1-0.6). Relative infant dose about 1-2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal if breastfeeding is initiated or discontinued. Generally compatible with breastfeeding in stable patients.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
No routine dose adjustment recommended. However, increased clearance in pregnancy may require dose titration based on clinical response. Monitor for withdrawal symptoms as pregnancy progresses; dose may need to be increased. Postpartum, dose may need to be reduced due to restored clearance.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
BUTRANS (buprenorphine transdermal system) is a Schedule III partial mu-opioid agonist used for chronic pain. Do not apply to irritated skin; rotate application sites to minimize skin reactions. Onset of analgesia is delayed (12-24 hours), so titrate with immediate-release analgesics as needed. Avoid concurrent use with full mu-opioid agonists (e.g., morphine) due to risk of precipitated withdrawal. The 5, 7.5, 10, 15, and 20 mcg/h patches are approved; 20 mcg/h is the maximum single dose. Reserve for patients tolerant to around-the-clock opioids (≥30 mg oral morphine equivalents/day). Monitor for respiratory depression (less than full agonists, but still a risk) and serotonin syndrome with other serotonergic agents.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
Apply the patch to clean, dry, hairless skin on the upper arm, chest, back, or side of the chest. Remove immediately if it falls off.,Wear the patch for 7 days; replace with a new patch at the same time of day. Do not cut or damage the patch.,Avoid exposure to direct heat (heating pads, saunas, hot tubs, prolonged sun) as it increases absorption and overdose risk.,Do not drink alcohol while using Butrans; it can cause dangerous side effects.,Keep all patches away from children and pets; used patches should be folded and flushed down the toilet immediately.,Do not stop abruptly or change dose without consulting your doctor; withdrawal may occur.,Common side effects include nausea, constipation, headache, and application site redness.
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTRANS vs MEMBRANEBLUE, answered by our medical review team.
BUTRANS is a Opioid Analgesic that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.. MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTRANS and MEMBRANEBLUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTRANS is: Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.. The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTRANS and MEMBRANEBLUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTRANS is classified as Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdraw. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.